404 related articles for article (PubMed ID: 27337847)
21. Multicenter, open-label study of long-term administration of febuxostat (TMX-67) in Japanese patients with hyperuricemia including gout.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S50-6. PubMed ID: 21654270
[TBL] [Abstract][Full Text] [Related]
22. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.
Kojima S; Matsui K; Ogawa H; Jinnouchi H; Hiramitsu S; Hayashi T; Yokota N; Kawai N; Tokutake E; Uchiyama K; Sugawara M; Kakuda H; Wakasa Y; Mori H; Hisatome I; Waki M; Ohya Y; Kimura K; Saito Y;
J Cardiol; 2017 Jan; 69(1):169-175. PubMed ID: 27005768
[TBL] [Abstract][Full Text] [Related]
23. How should we manage asymptomatic hyperuricemia?
Chalès G
Joint Bone Spine; 2019 Jul; 86(4):437-443. PubMed ID: 30316974
[TBL] [Abstract][Full Text] [Related]
24. Current and future therapeutic options for the management of gout.
Whelton A
Am J Ther; 2010; 17(4):402-17. PubMed ID: 20562597
[TBL] [Abstract][Full Text] [Related]
25. Understanding treatments for gout.
Cannella AC; Mikuls TR
Am J Manag Care; 2005 Nov; 11(15 Suppl):S451-8; quiz S465-8. PubMed ID: 16300459
[TBL] [Abstract][Full Text] [Related]
26. Effects of serum uric acid on blood-pressure lowering treatment.
Grassi G
Curr Med Res Opin; 2017 Nov; 33(sup3):15-19. PubMed ID: 28952389
[TBL] [Abstract][Full Text] [Related]
27. Why focus on uric acid?
Johnson RJ
Curr Med Res Opin; 2015; 31 Suppl 2():3-7. PubMed ID: 26414730
[TBL] [Abstract][Full Text] [Related]
28. The role of uric acid in the development of cardiovascular disease.
Borghi C
Curr Med Res Opin; 2015; 31 Suppl 2():1-2. PubMed ID: 26414729
[TBL] [Abstract][Full Text] [Related]
29. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
30. Hyperuricemia: a novel old disorder-relationship and potential mechanisms in heart failure.
Borghi C; Palazzuoli A; Landolfo M; Cosentino E
Heart Fail Rev; 2020 Jan; 25(1):43-51. PubMed ID: 31745840
[TBL] [Abstract][Full Text] [Related]
31. Comment on: Gout: an independent risk factor for all-cause and cardiovascular mortality.
Mascitelli L; Pezzetta F; Goldstein MR
Rheumatology (Oxford); 2010 Jul; 49(7):1421-2; author reply 1422. PubMed ID: 20427295
[No Abstract] [Full Text] [Related]
32. Hyperuricaemia: more than just a cause of gout?
Katsiki N; Karagiannis A; Athyros VG; Mikhailidis DP
J Cardiovasc Med (Hagerstown); 2013 Jun; 14(6):397-402. PubMed ID: 23032963
[TBL] [Abstract][Full Text] [Related]
33. Hyperuricemia, gout, and cardiovascular disease--an important "muddle".
Keenan RT; Pillinger MH
Bull NYU Hosp Jt Dis; 2009; 67(3):285-90. PubMed ID: 19852752
[TBL] [Abstract][Full Text] [Related]
34. Gout and hyperuricemia.
Chilappa CS; Aronow WS; Shapiro D; Sperber K; Patel U; Ash JY
Compr Ther; 2010; 36():3-13. PubMed ID: 21229813
[TBL] [Abstract][Full Text] [Related]
35. Study on the anti-gout activity of chlorogenic acid: improvement on hyperuricemia and gouty inflammation.
Meng ZQ; Tang ZH; Yan YX; Guo CR; Cao L; Ding G; Huang WZ; Wang ZZ; Wang KD; Xiao W; Yang ZL
Am J Chin Med; 2014; 42(6):1471-83. PubMed ID: 25384446
[TBL] [Abstract][Full Text] [Related]
36. Uric acid: role in cardiovascular disease and effects of losartan.
Alderman M; Aiyer KJ
Curr Med Res Opin; 2004 Mar; 20(3):369-79. PubMed ID: 15025846
[TBL] [Abstract][Full Text] [Related]
37. Uric acid as a cardiorenal risk factor - ready for prime-time?
Patel KH; Goldsmith DJ
Int J Clin Pract; 2014 Jul; 68(7):796-801. PubMed ID: 24942307
[TBL] [Abstract][Full Text] [Related]
38. Crystal ball gazing: new therapeutic targets for hyperuricaemia and gout.
Dalbeth N; Merriman T
Rheumatology (Oxford); 2009 Mar; 48(3):222-6. PubMed ID: 19109320
[TBL] [Abstract][Full Text] [Related]
39. Update on gout: pathophysiology and potential treatments.
Abeles AM; Park JY; Pillinger MH; Cronstein BN
Curr Pain Headache Rep; 2007 Dec; 11(6):440-6. PubMed ID: 18173979
[TBL] [Abstract][Full Text] [Related]
40. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
